• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1998 Fiscal Year Final Research Report Summary

Studies on concurrent radiotherapy and chemotherapy to point to preservation of the prgan and function for head and neck cancer

Research Project

Project/Area Number 08671944
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Otorhinolaryngology
Research InstitutionHOKKAIDO UNIVERSITY

Principal Investigator

INUYAMA Yukio  Sch.of Med., Hokkaido Univ., Pro., 医学部, 教授 (70051480)

Co-Investigator(Kenkyū-buntansha) FURUTA Yasushi  Med.Hospital, Hokkaido Univ., Lec., 医学部・附属病院, 講師 (60261301)
SHIRATO Hiroki  Sch.of Med., Hokkaido Univ., Asso.Pro., 医学部, 助教授 (20187537)
FUKUDA Satoshi  Sch.of Med., Hokkaido Univ., Asso.Pro., 医学部, 助教授 (20125347)
Project Period (FY) 1996 – 1998
Keywordshead and neck cancer / concurrent radiotherapy and chemotherapy / carboplatin / cisplatin / organ preservation / toxicity / quality of life
Research Abstract

The trial of concurrent carboplatin (CBDCA) and radiotherapy for head and neck was initiated in 1990. As a result a better survival was achieved in cancers of the larynx, the oral cavity and the paranasal sinuses. Interestingly the overall survival with larynx preservation was better in the concurrent CBDCA and radio-therapy group than in radiation alone group. So the randomized controlled study has been conducted between CBDCA + Rad and CDDP + Rad group since 1995. The 96 patients were randomized into two groups : CBDCA group 50 cases vs CDDP group 46 cases. The 78 cases were completed ; CBDCA group : 41/50 and CDDP group : 37/46. The 3-year survivals of the complete cases were 87.8% in CBDCA group and 61.5% in CDDP group respectively. If we look at 3-year survival by primary site, CBDCA group : 100% and CDDP group : 64.3% in the oropharynx, CBDCA group : 60% and CDDP group : 83.3% in the hypopharynx, and CBDCA group : 94.1% and CDDP group : 63.2%, respectively. But there was no statistically significant difference between CBDCA group and CDDP group. Furthermore looking at the 3-year survival with larynx preservation, the results were as follows ; glottic : CBDCA : 86.7% vs CDDP : 55.6% (n.s.), supraglottic : CBDCA : 85.7% vs CDDP : 13.9% (p=0.0241). As for T2 cases, there was a significantly difference between the two groups ; CBDGA : 90% vs CDDP 42.1% (p=0.0097). In terms of toxicity, lower incidence and grade of mucositis, and severer bone marrow suppression were observed in CBDCA group, meanwhile higher incidence and grade of mucositis, and lower bone marrow suppression appeared in CDDP group.

  • Research Products

    (16 results)

All Other

All Publications (16 results)

  • [Publications] 犬山 征夫 他3名: "(特集) 放射線治療・化学療法併用の適応となる頭頸部早期癌" JOHNS. 13・4. 567-573 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Inuyama Y 他8名: "The role of chemotherapy in the treatment of the head and neck." Jpn J Cancer Chemother. 24・補1. 52-59 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 犬山 征夫: "QOLからみた頭頸部癌治療の進歩, Prologue ; QOLからみた頭頸部癌治療の現状" 癌治療とQOL. 2.3・2. 3 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 犬山 征夫: "頭頸部癌治療の最前線,頭頸部癌の最前線-現状と将来-" 癌の臨床. 44・11. 1127-1134 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 犬山 征夫 他2名: "頭頸部癌治療の最前線.中咽頭・口腔癌に対するChemoradiation." 癌の臨床. 44・11. 1253-1260 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 犬山 征夫 他4名: "5.声帯癌T3症例の保存的治療. (2)北海道大学病院の場合" 耳喉頭頸. 70・12. 799-804 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 犬山 征夫 編著: "頭頸部癌治療における化学療法の役割" 東京医学社, 467 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 犬山 征夫 監修: "頭頸部がんの境界領域における治療法の最新の進歩" 協和企画通信, 131 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Inuyama Y.et.al.: "Early cancer of the head and neck" JOHNS. 13-4. 567-573 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Inuyama Y.et.al.: "The role of chemotherapy in the treatment of the head and neck" Jpn.J.Cancer Chemother. 24suppll. 52-59 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Inuyama Y.: "Advances in the treatment of the head and neck ; From viewpoint of QOL" Cancer Treatment and QOL. part2,3 (2). 3 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Inuyama Y.: "The front line of head and neck cancer -Current status and future-" Jap.J.Cancer Clin.44-11. 1127-1134 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Inuyama Y.et.al.: "Chemoradiation for cancer of the oropharynx and oral cavity" Jap.J.Cancer Clin.44-11. 1253-1260 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Inuyama Y.et.al.: "Treatment with larynx preservation for T3 cases of larayngeal cancer" Jibi Inkoka.Tokeibu Geka. 70-12. 799-804 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Inuyama Y.: The Role of Chemotherapy in the Treatment of Head and Neck Cancer. Tokyo Igakusha, 1-467 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Inuyama Y.: Recent Advances of the Treatment in Boundary Province of Head and Neck Cancer. Kyowa Kikaku Tushin, 1-131 (1996)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1999-12-08  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi